MMDx for Molecular Biopsy Assessment

Innovative software leveraging gene expression data from biopsied heart and kidney tissue

This service can provide information that can supplement diagnoses of allograft injury via histopathology and other parameters.


MMDx for molecular biopsy assessment key features and benefits 

  • Easily incorporated and processed: Sample is taken from the existing biopsy and placed into the provided tube (containing RNAlater), and shipped at room temperature
  • Fast turnaround: Results available in as little as 24-48 hours after receipt of sample

The value of gene expression profiling

In the post-transplant setting, data derived from the molecular profile of a biopsy can signal ongoing and often subclinical immune-mediated injury, as well as identify acute T cell-mediated rejection, even in samples without histological evidence of inflammation.1  This approach helps to overcome the limitations of conventional biopsy diagnosis, which often relies on histopathology scores that are empirically derived, subjective, and opinion-based.

Manage post-transplant treatment with confidence

MMDx Heart and MMDx Kidney complement conventional biopsy processing to help improve the assessment of rejection and injury in transplanted organs. These Laboratory Developed Tests use a GeneChip Custom Microarray to measure mRNA transcript levels in biopsies along with extensive big data derived from individuals and populations. The MMDx Heart and MMDx Kidney systems combine these technologies to deliver objective and reproducible transplant biopsy assessments on a molecular level.

"Using an objective scientific approach instead of by eye, we can look at the molecular signature of a biopsy to make a more accurate diagnosis."

Andrew Fisher, PhD,

Institute of Transplantation at Freeman Hospital Newcastle Upon Tyne, United Kingdom

How does the process work?

  • mRNA is produced inside transplanted tissue when DNA genes are expressed or active

  • Depending on the risk or severity of organ rejection and injury, particular genes will be activated and produce unique patterns of mRNA

  • Thousands of different mRNA are accurately analyzed. The biopsy report provides a summary of key findings (eg, inflammation, acute kidney injury and atrophy-fibrosis scores and different rejection classifier scores) as well as the overall molecular interpretation

From specimen collection to biopsy report: the MMDx process

Obtaining results starts with requesting a free Specimen Collection Kit. 
The illustration below shows how the sample is analyzed and the biopsy report is generated and made available to clinicians. 

Order your free Specimen Collection Kit⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀

Coverage information for post-transplant kidney monitoring

MMDx-Heart and MMDx-Kidney are tests that were developed and validated by Kashi Clinical Laboratories, Inc. The laboratory developed tests are used for clinical purposes by the CLIA-certified laboratory performing the test. These tests have not been cleared or approved by the US FDA or CE marked in the EU as an in vitro diagnostic test.


© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise noted. MMDx and Molecular Microscope are trademarks of Transcriptome Sciences Inc.